Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Shares Outstanding (Weighted Average): 2023-2024

Historic Shares Outstanding (Weighted Average) for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $25.8 million.

  • Contineum Therapeutics' Shares Outstanding (Weighted Average) rose 9.01% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 9.01%. This contributed to the annual value of $25.8 million for FY2024, which is 41.20% up from last year.
  • Per Contineum Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $25.8 million for FY2024, which was up 41.20% from $18.3 million recorded in FY2023.
  • Contineum Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $25.8 million for FY2024, and its period low was $18.3 million during FY2023.
  • Its 2-year average for Shares Outstanding (Weighted Average) is $22.0 million, with a median of $22.0 million in 2023.
  • Data for Contineum Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY surged of 41.20% (in 2024) over the last 5 years.
  • Over the past 2 years, Contineum Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $18.3 million in 2023, then surged by 41.20% to $25.8 million in 2024.